In the ECHO-305/KEYNOTE-654 study, the addition of epacadostat 100 mg BID to pembrolizumab did not improve ORR in patients with previously untreated metastatic PD-L1 TPS ≥ 50% NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.